Skip to main content
AmigoFish

Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity

From The BioCentury Show · · 35 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower relative to the broader healthcare environment, SoftBank’s Jacqueline Fok said on The BioCentury Show. In conversation with BioCentury's Stephen Hansen, Fok, who is investment director, Life Sciences & Health Tech at SoftBank Investment Advisers, also detailed SoftBank’s investment strategy in life sciences and the opportunity the U.K. has to stand out as a globally competitive player, with SoftBank’s obesity portfolio company Metsera as a recent example of success.

View full story: https://www.biocentury.com/article/658661

#ArtificialIntelligence #DrugDevelopment #BiotechInvestment #UKBiotech #ObesityDrugDevelopment

00:00 - Introduction 01:30 - SoftBank Strategy 08:40 - Metsera 14:48 - U.K. Biotech 21:38 - AI 28:20 - Women in Leadership 32:03 - Fok’s Catalysts

Back to The BioCentury Show · Report a problem